Since Par-4 is remarkably decreased in cancer tissues4 and BCG immunotherapy has been used successfully as a treatment modality for prostate and bladder cancer18, we hypothesized that Par-4 induction by mycobacterial infection may contribute to the inhibition of bladder cancer cell growth. This evidence concerns the gene PAWR and urinary bladder carcinoma.